The Role of T Cell Immunity in Monoclonal Gammopathy and Multiple Myeloma: From Immunopathogenesis to Novel Therapeutic Approaches
Authors:
- Ivana LagrecaILIvana Lagreca
- Giovanni RivaGRGiovanni Riva
- Vincenzo NasilloVNVincenzo Nasillo
- Patrizia BarozziPBPatrizia Barozzi
- Ilaria CastelliICIlaria Castelli
- Sabrina BassoSBSabrina Basso
- Francesca BettelliFBFrancesca Bettelli
- Davide GiustiDGDavide Giusti
- Angela CuoghiACAngela Cuoghi
- Paola BrescianiPBPaola Bresciani
- Andrea MesserottiAMAndrea Messerotti
- Andrea GilioliAGAndrea Gilioli
Open Access
- 8 May 2022
- journal article
- review article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 23 (9) , 5242
Abstract
Multiple Myeloma (MM) is a malignant growth of clonal plasma cells, typically arising from asymptomatic precursor conditions, namely monoclonal gammopathy of undetermined significance (MGUS) and smoldering MM (SMM). Profound immunological dysfunctions and cytokine deregulation are known to characterize the evolution of the disease, allowing immune escape and proliferation of neoplastic plasma cells. In the past decades, several studies have shown that the immune system can recognize MGUS and MM clonal cells, suggesting that anti-myeloma T cell immunity could be harnessed for therapeutic purposes. In line with this notion, chimeric antigen receptor T cell (CAR-T) therapy is emerging as a novel treatment in MM, especially in the relapsed/refractory disease setting. In this review, we focus on the pivotal contribution of T cell impairment in the immunopathogenesis of plasma cell dyscrasias and, in particular, in the disease progression from MGUS to SMM and MM, highlighting the potentials of T cell-based immunotherapeutic approaches in these settings.Keywords
This publication has 159 references indexed in Scilit:
- Long-term survival in multiple myeloma is associated with a distinct immunological profile, which includes proliferative cytotoxic T-cell clones and a favourable Treg/Th17 balanceBlood Cancer Journal, 2013
- The frequency of T regulatory cells modulates the survival of multiple myeloma patients: detailed characterisation of immune status in multiple myelomaBritish Journal of Cancer, 2012
- Elevated IL-17 produced by Th17 cells promotes myeloma cell growth and inhibits immune function in multiple myelomaBlood, 2010
- Functional Interaction of Plasmacytoid Dendritic Cells with Multiple Myeloma Cells: A Therapeutic TargetCancer Cell, 2009
- Myeloid-derived suppressor cells as regulators of the immune systemNature Reviews Immunology, 2009
- Dendritic cells mediate the induction of polyfunctional human IL17-producing cells (Th17-1 cells) enriched in the bone marrow of patients with myelomaBlood, 2008
- Dickkopf-1 (DKK1) is a widely expressed and potent tumor-associated antigen in multiple myelomaBlood, 2007
- Vasculogenic mimicry by bone marrow macrophages in patients with multiple myelomaOncogene, 2007
- Frequent and specific immunity to the embryonal stem cell–associated antigen SOX2 in patients with monoclonal gammopathyJournal of Experimental Medicine, 2007
- Expansion of FOXP3high regulatory T cells by human dendritic cells (DCs) in vitro and after injection of cytokine-matured DCs in myeloma patientsBlood, 2006